Abstracts

STOPPING SECONDARY TE PROPHYLAXIS IN SUPPRESSED PATIENTS WITH CD4 100-200 IS NOT SAFE

Current guidelines recommend that secondary Toxoplasma gondii prophylaxis can be safely discontinued in HIV-infected patients with suppressed viremia on antiretroviral therapy (ART) and a CD4 cell count >200 cells/mm3. Whether such a policy can be extended to patients with CD4 cell counts between 100-200 cells/mm3 is unknown. The Collaboration of Observational HIV Epidemiological Research in…

DOSING FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE

Fetal antiretroviral exposure is usually derived from the cord-to-maternal (ctm) concentration ratio. This static parameter does not provide information on the pharmacokinetics in utero, limiting the assessment of a fetal exposure-effect relationship. Pregnancy physiologically-based pharmacokinetic (p-PBPK) modeling could provide a solution, although incorporation of placental antiretroviral transfer remains challenging. Here, we aimed to incorporate placental…

VIRAL CONTROL INDUCED BY HIVCONSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS

The combined use of therapeutic vaccination and specific drugs that can reactivate latent reservoir virus (Kick and kill strategies) hold the promise to achieve a functional cure for HIV infection. The recently completed BCN01 vaccine trial (NCT01712425) consisted in a ChAd.HIVconsv and MVA.HIVconsv prime/boost vaccination in early treated individuals (<6 months from HIV acquisition) and…

TELMISARTAN DOES NOT IMPROVE LYMPH NODE OR FAT FIBROSIS IN TREATED HIV INFECTION

Chronic HIV infection is characterized by persistent inflammation and immune activation that can lead to tissue injury and fibrosis. Lymph node (LN) fibrosis may limit CD4+ T-cell recovery; LN and adipose tissue (AT) fibrosis may contribute to systemic inflammation and comorbidities. Telmisartan is an angiotensin receptor blocker and PPAR-γ agonist with anti-inflammatory and anti-fibrotic properties.…

PHARMACOLOGIC INHIBITION OF IDO BLUNTS FEATURES OF SIV-RELATED CHRONIC INFLAMMATION

The immunomodulatory and neurotoxic activities of kynurenines derived from tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO1) play a role in sustaining a cycle of inflammation and immune dysfunction during HIV infection. Such a cycle may lead to increased risks of non-AIDS diseases, such as liver disease and neurocognitive impairment, despite effective cART. We hypothesized that inhibition of…